BBT‐176, a novel fourth‐generation tyrosine kinase inhibitor (TKI), has shown promising efficacy in patients with osimertinib‐resistant EGFR mutations in NSCLC.129. This evidence concerns the gene EGFR and non-small cell lung carcinoma.